share_log

Syntara Ltd: Presentation: Phase 2 study of SNT-5505 in myelofibrosis

ASX ·  Dec 10, 2024 09:31
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more